SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20 at ESGCT Congress
Paris, October 3, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, announces today that it will be presenting data on its two lead gene-independent assets, SPVN06 and SPVN20, at the European Society of Gene and Cell Therapies (ESGCT)-29th Congress to be held from 11-14 October in Edinburgh, UK.
More information below:
Poster Presentation: AAV delivery of G protein gated K+ channel increases cone-mediated vision in the rd10 mouse model of Retinitis Pigmentosa
Date and Time: 12th October, poster #P219
Presenter: Dr. Hanen Khabou
Room: Cromdale Hall, level -2.
Poster Presentation: Gene-independent strategies for cone preservation in inherited rod-cone dystrophies
Date and Time: 12th October, poster #P225
Presenter: Laure Blouin
Room: Cromdale Hall, level -2.
Poster Presentation: Development and qualification of a relative potency assay for SPVN06, a recombinant AAV vector for the treatment of inherited retinal disorders
Date and Time: 12th October, poster #P347
Presenter: Charles River in collaboration with SparingVision
Room: Cromdale Hall, level -2.
Poster Presentation: Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies
Date and Time: 13th October, poster #P228
Presenter: Dr. Anne-Sophie Gautron
Room: Cromdale Hall, level -2.
**ENDS**